While LH-RH analogs have been widely used in prostate cancer and studied in BPH treatment by reducing androgen levels, GH-RH antagonists offer a distinct mechanism by inhibiting growth factors, inflammatory pathways, and cellular signaling involved in prostate enlargement. Here, GNRH1 is linked to benign prostatic hyperplasia.